Show simple item record

dc.contributor.authorJones, Kimberlyen_US
dc.contributor.authorP. Nourse, Jamieen_US
dc.contributor.authorKeane, Colmen_US
dc.contributor.authorBhatnagar, Atulen_US
dc.contributor.authorK. Gandhi, Maheren_US
dc.date.accessioned2017-05-03T11:58:08Z
dc.date.available2017-05-03T11:58:08Z
dc.date.issued2014en_US
dc.identifier.issn10780432en_US
dc.identifier.doi10.1158/1078-0432.CCR-13-1024en_US
dc.identifier.urihttp://hdl.handle.net/10072/66741
dc.description.abstractPURPOSE: Although microRNAs (miRNA) show potential as diagnostic biomarkers in cancer, their role as circulating cell-free disease response biomarkers remains unknown. Candidate circulating miRNA biomarkers for classical Hodgkin lymphoma (cHL) might arise from Hodgkin-Reed-Sternberg (HRS) cells and/or nonmalignant tumor-infiltrating cells. HRS cells are sparse within the diseased node, embedded within a benign microenvironment, the composition of which is distinct from that seen in healthy lymph nodes. EXPERIMENTAL DESIGN: Microarray profiling of more than 1,000 human miRNAs in 14 cHL primary tissues and eight healthy lymph nodes revealed a number of new disease node-associated miRNAs, including miR-494 and miR-1973. Using quantitative real-time PCR (qRT-PCR), we tested the utility of these, as well as previously identified disease node-associated plasma miRNAs (including miR-21 and miR-155), as disease response biomarkers in a prospective cohort of 42 patients with cHL. Blood samples were taken in conjunction with radiologic imaging at fixed time points before, during, and after therapy. Absolute quantification was used so as to facilitate implementation in diagnostic laboratories. RESULTS: Levels of miR-494, miR-1973, and miR-21 were higher in patients than control (n = 20) plasma (P = 0.004, P = 0.007, and P < 0.0001, respectively). MiR-494 and miR-21 associated with Hasenclever scores =3. Strikingly, all three miRNAs returned to normal at remission (P = 0.0006, P = 0.0002, and P < 0.0001 respectively). However, only miR-494 and miR-1973 reflected interim therapy response with reduction being more pronounced in patients achieving complete versus partial responses (P = 0.043 and P = 0.0012, respectively). CONCLUSION: Our results demonstrate that in patients with cHL, circulating cell-free miRNAs can reflect disease response once therapy has commenced.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.languageEnglishen_US
dc.publisherAmerican Association for Cancer Researchen_US
dc.publisher.placeUnited Statesen_US
dc.relation.ispartofstudentpublicationYen_US
dc.relation.ispartofpagefrom253en_US
dc.relation.ispartofpageto264en_US
dc.relation.ispartofissue1en_US
dc.relation.ispartofjournalClinical Cancer Researchen_US
dc.relation.ispartofvolume20en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchCancer Therapy (excl. Chemotherapy and Radiation Therapy)en_US
dc.subject.fieldofresearchcode111204en_US
dc.titlePlasma microRNA are disease response biomarkers in classical Hodgkin lymphomaen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.hasfulltextNo Full Text
gro.griffith.authorKeane, Colm


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record